MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2022 International Congress

    Frequency-specific dynamics of beta oscillations: Critical for tuning adaptive DBS

    LC. Alva, F. Torrecillos, A. Averna, E. Bernasconi, M. Bange, A. Mostofi, A. Pogosyan, P. Fischer, M. Muthuraman, K. Ashkan, S. Groppa, EA. Pereira, H. Tan, G. Tinkhauser (Bern, Switzerland)

    Objective: Different frequencies within the beta range may have distinct temporal dynamics and an individual assessment should be performed to select the optimal feedback signal…
  • 2022 International Congress

    Experience with apomorphine infusion cartridge in France – evaluation of patient and healthcare team benefits

    M. Vérin, M. Demais (Rennes, France)

    Objective: To evaluate ‘real-world’ benefits for patients with Parkinson’s disease (PD) and impact on healthcare team practice of the introduction of apomorphine infusion (APO) cartridge…
  • 2022 International Congress

    The 20-item Noise Pareidolia Task is uniquely sensitive to Visual Hallucinations in Parkinson’s Disease

    T. Turner, F. Rodriguez-Porcel (Charleston, USA)

    Objective: The purpose of this study was to examine clinical utility of the 20-item Noise Pareidolia Task (NPT20) in Parkinson’s disease (PD), as indicated by…
  • 2022 International Congress

    USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.

    AK. Vargas Mendoza, B. López López, M. Díaz Castela, J. Molina Gil, P. Zunzunegui Arroyo, A. Criado Antón, ME. Suárez Sanmartín, C. García Fernández (Oviedo, Spain)

    Objective: The aim of this study is to evaluate the feasibility, efficacy and safety of NCSAI administration in patients with Advanced Parkinson disease (APD). Background:…
  • 2022 International Congress

    Mapping Side Effects in Deep Brain Stimulation – Different Approaches, Different Problems.

    TA. Dembek, H. Jergas, JN. Petry-Schmelzer, C. Baldermann, J. Strelow, A. Nehls, V. Visser-Vandewalle, MT. Barbe (Cologne, Germany)

    Objective: This study aims to evaluate different strategies to map DBS‑induced side‑effects regarding their ability to create anatomically plausible stimulation maps and to predict side‑effect…
  • 2022 International Congress

    Meta-optimization to select stimulation settings for deep brain stimulation in Parkinson’s disease

    M. Connolly, F. Isbaine, J. Willie, R. Gross, A. Devergnas, S. Miocinovic (Atlanta, USA)

    Objective: The objective is to develop an algorithmic approach for selecting deep brain stimulation (DBS) settings for Parkinson’s disease (PD) and other movement disorders more…
  • 2022 International Congress

    The cortical thickness signature and future phenoconversion in isolated REM-sleep behavior disorder: a longitudinal analysis

    JH. Shin, JY. Lee, HJ. Kim, YK. Kim, EJ. Yoon, HW. Nam, B. Jeon (Seoul, Republic of Korea)

    Objective: To develop an imaging biomarker predicting subtype-specific phenoconversion in isolated REM sleep behavior disorder (iRBD), we aim at identifying MRI-driven cortical thickness signature in…
  • 2022 International Congress

    Directional DBS – Early experiences with “Current steering” in India

    VM. Mathur, PD. Doshi, AA. Aundhkar, MB. Baldia, PW. Wadia (Mumbai, India)

    Objective: Deep Brain Stimulation using directional leads is relatively recent in India. We present our early experiences with the same. Background: Deep brain stimulation (DBS)…
  • 2022 International Congress

    Increased alpha-synuclein level in primary macrophages derived from patients with Parkinson’s disease

    A. Kopytova, M. Nikolaev, G. Baydakova, A. Izymchenko, D. Bogdanova, I. Miliukhina, A. Emelyanov, E. Zakharova, S. Pchelina (Gatchina, Russian Federation)

    Objective: To assess glucocerebrosidase and alpha-synuclein level in primary macrophages derived from patients with Parkinson’s disease with and without GBA1 mutation. Background: Parkinson’s disease (PD)…
  • 2022 International Congress

    IgG to neurotensin in blood of Parkinson’s disease patients

    Z. Muruzheva, M. Absalyamova (Saint-Petersburg, Russian Federation)

    Objective: The aim of the study was measurement of IgG to NT in blood plasma of Parkinson's disease patients. Background: Neurotensin (NT) is a 13-amino-acid…
  • « Previous Page
  • 1
  • …
  • 449
  • 450
  • 451
  • 452
  • 453
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley